Shanghai Changzheng Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shczyy.com
Clinical Trials
111
Active:2
Completed:11
Trial Phases
6 Phases
Early Phase 1:14
Phase 1:9
Phase 2:21
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (92 trials with phase data)• Click on a phase to view related trials
Not Applicable
34 (37.0%)Phase 2
21 (22.8%)Early Phase 1
14 (15.2%)Phase 4
13 (14.1%)Phase 1
9 (9.8%)Phase 3
1 (1.1%)A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
Not Applicable
Recruiting
- Conditions
- Colorectal Cancer MetastaticColorectal Cancer RecurrentColorectal Cancer Stage IV
- Interventions
- Drug: CD-GA-102
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07050394
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, None Selected, China
Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
Not yet recruiting
- Conditions
- Metabolic SyndromeDiabetesObesity and OverweightHypertensionDyslipidemiaThyroid DiseasesBone Metabolism DisorderChronic Kidney Disease(CKD)Cardiovascular Diseases (CVD)Cardiovascular-kidney-metabolic Syndrome
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 4094
- Registration Number
- NCT07043166
Evaluation of the Efficacy and Safety of Absorbable vs Traditional Bone Wax for Facet Fusion After Lumbar Fusion Surgery
Not Applicable
Not yet recruiting
- Conditions
- Lumbar Fusion SurgeryFusion of Joint
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 330
- Registration Number
- NCT07040293
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
Phase 1
Not yet recruiting
- Conditions
- Lupus Nephritis (LN)ANCA-Associated Glomerulonephritis
- Interventions
- Drug: Injection of MSC303
- First Posted Date
- 2025-06-02
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT07000292
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
HiSCs in the Treatment of Rheumatoid Arthritis
Not Applicable
Not yet recruiting
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Biological: hiSCs
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06947746
- Locations
- 🇨🇳
Shanghai ChangZheng hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 22
- Next
News
First-in-Human iPSC-CAR-NK Cell Therapy Shows Promise for Autoimmune Disease Treatment
Qihan Biotech's QN-139b represents the first-ever application of iPSC-CAR-NK cells in treating autoimmune disease, successfully inducing immune reset in a patient with refractory systemic sclerosis.